Trial Profile
Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid, Durlaza in CVD (Cardiovascular Disease) Patients at Risk of High Platelet Turnover
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aspirin (Primary)
- Indications Cardiovascular disorders
- Focus Pharmacodynamics
- Acronyms DURATION
- Sponsors New Haven Pharmaceuticals
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
- 10 Nov 2015 According to a New Haven Pharmaceuticals media release, results were presented at the American Heart Association's Scientific Sessions event.
- 10 Nov 2015 Results published in the Media Release